Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Rheumatic Heart Disease I: Introduction
The JAK-STAT Signaling Pathway
T Cell Types and Functions
Chronic Inflammation: Introduction
Inflammatory Bowel Disease III: Crohn's Disease
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: May 11, 2026

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
Alexander So1, Annette Ives, Leo A B Joosten
1Service of Rheumatology, Department of Musculoskeletal Medicine, Avenue Pierre Decker 4, Centre Hospitalier Universitaire Vaudois and University of Lausanne, 1011 Lausanne, Switzerland. alexanderkai-lik.so@ chuv.ch
Inflammasomes, particularly NLRP3, drive inflammation in rheumatic diseases by releasing IL-1β and IL-18. Targeting IL-1 offers therapeutic potential for these conditions.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: